Thank you for your comprehensive and educational post.
For me, a newbie in biotech stocks you and your learned colleagues are great teachers. Please do write when you have time. All the best to you.
What a knowledgeable and caring board.
I have been here for only one day and am already in your debt:
Thank you “tennisoutofgas” for mentioning “Medical Technology Newsletter”
Thank you “borntoshop1200” for sharing your “30 years” of experience and record keeping
Thank you “symptom88” for your illumination and addition to the board discussion
Thank you ALL for being so much in the know and so civil & kind to new posters.
Form this day forward I will be your fan and follower. THANK YOU.
Do mean 30 years with Medical Technology Newsletter? If so, that means they are very good.
Thank you for your reply in advance.
Anthera to receive up to $48,000,000 plus future product margin on commercial supply
- Zenyaku to reimburse Anthera for a portion of future blisibimod worldwide development costs
- Zenyaku to assume full responsibility for development and associated costs in Japan and potentially other Asian territories in the future
- Companies will collaborate on blisibimod development for both IgA Nephropathy ("IgAN") and Systemic Lupus Erythematosus ("Lupus")
Anthera Pharmaceuticals Licenses Japan Rights for Blisibimod to Zenyaku Kogyo Co., Ltd.
Source: yahoo news